Iv Associates Lp Dp Net Worth

What's Iv Dp's mailing address?

Iv's mailing address filed with the SEC is C/O DOMAIN ASSOCIATES, LLC, ONE PALMER SQUARE, PRINCETON, NJ, 08542.

Insiders trading at Nuvasive Inc

Over the last 22 years, insiders at Nuvasive Inc have traded over $60,917,905 worth of Nuvasive Inc stock and bought 185,079 units worth $8,372,956 . The most active insiders traders include Jesse I Treu, James C Blair, and Brian H Dovey. On average, Nuvasive Inc executives and independent directors trade stock every 11 days with the average trade being worth of $415,308. The most recent stock trade was executed by Marc W. Rosenbaum on 1 March 2023, trading 1,829 units of NUVA stock currently worth $72,703.

What does Nuvasive Inc do?

nuvasive® is a place where we create new and innovative products at a speed that drives our ability to deliver absolute responsiveness®, and gives us a competitive edge. at nuvasive, we empower our shareowners to influence results and significantly contribute to the success of the company. together we make nuvasive a leader in the spine industry with our unique focus on speed of innovation®. every member of the nuvasive family has the opportunity to improve the lives of patients through their work. these life-changing career paths show how hard work, a competitive spirit and your unwavering dedication to the patient can take you and your career to new places. in addition to being a great place to have a career, we’re also committed to giving back and supporting our communities. through an attitude of gratitude, nuvasive provides life-changing spinal surgery to disadvantaged communities through our nonprofit, the nuvasive spine foundation®, and offers patient-to-patient support through

Nuvasive Inc executives and stock owners

Nuvasive Inc executives and other stock owners filed with the SEC include:

• J. Christopher Barry,
  Chief Executive Officer, Director
• J. Christopher Barry,
  CEO & Director
• Nathaniel Sisitsky,
  Senior Vice President, General Counsel, Corporate Secretary
• Matthew K. Harbaugh,
  Exec. VP & CFO
• Gregory Lucier,
  Chairman of the Board
• Nathaniel B. Sisitsky Esq.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Lucas Vitale,
  Sr. VP & Chief HR Officer
• Donald Rosenberg,
  Independent Director
• Daniel Wolterman,
  Independent Director
• Vickie Capps,
  Independent Director
• Leslie Norwalk,
  Independent Director
• R. Scott Huennekens,
  Independent Director
• Robert Friel,
  Independent Director
• John DeFord,
  Independent Director
• Suzanne Hatcher,
  Vice President, Internal & External Affairs
• Dale Wolf,
  Senior Vice President - Global Operations
• Massimo Calafiore,
  Executive Vice President - Global Business Units
• Brent Boucher,
  Executive Vice President - Global Commercial
• Lucas Vitale,
  Chief Human Resource Officer
• Matthew Harbaugh,
  Executive Vice President, Chief Financial Officer
• Marc Rosenbaum,
  VP, Corp. Controller & Chief Accounting Officer
• Michael Farrington,
  VP of Corp. Marketing, Brand & Communication
• Juliet C. Cunningham,
  VP of Investor Relations
• Ryan Donahoe,
  Chief Technology Officer
• Dale A. Wolf,
  Sr. VP of Global Operations
• Lisa Pecora,
  VP & Head of Global Commercial Fin.
• Frank Middeke,
  Managing Director of DACH
• Sean Freeman,
  Sr. VP of Strategy & Corp. Devel.
• Johnson Lai,
  Chief Information Officer
• Jereme M Sylvain,
  Chief Accounting Officer
• Jack R Blair,
  Director
• Peter Michael Leddy,
  Director
• Edmund J Roschak,
  CEO, NuVasive Spec. Orthopedic
• Dan Wolterman,
  Director
• Michael D Ohalleran,
  Director
• Lesley H Howe,
  Director
• Peter C Farrell,
  Director
• Joan Stafslien,
  EVP and General Counsel
• Quentin S. Blackford,
  CFO and CAO
• Cox Carol,
  EVP Strategy, Corp Dev
• Tyler Lipschultz,
  EVP, Biologics
• Andrew C. Morton,
  SVP, CHRO
• Matthew Link,
  President
• Rajesh Asarpota,
  CFO
• Paul Mc Clintock,
  President, U.S. Commercial
• Stephen Rozow,
  EVP, Global Process
• Jeffrey P Rydin,
  Senior V.P., U.S. Sales
• Jason Hannon,
  VP, Legal Affairs & Secretary
• Patrick Miles,
  Senior VP, Marketing
• Kevin C Oboyle,
  CFO and Executive VP
• James C Blair,
  Director
• James J Skinner,
  VP,Strategic Sales Development
• Jonathan Spangler,
  VP & Chief Patent Counsel
• G Bryan Cornwall,
  VP, Research & Development
• Hansen A Yuan,
  Director
• Arda Minocherhomjee,
  Director
• Blair Capital Management Vi...,
  
• Perkins Caufield & Byers Vi...,
  10% owner
• Joseph Lacob,
  Director
• G Rogan Fry,
  Sr. V. P., Corp. Development
• Viii Associates Lp Kpcb,
  10% owner
• Life Sciences Zaibatsu Fund...,
  10% owner
• Iv Associates Lp Dp,
  10% owner
• Jesse I Treu,
  10% owner
• Kathleen K Schoemaker,
  10% owner
• Brian H Dovey,
  10% owner
• Vii Associates Lp Kpcb,
  10% owner
• De Depot Et Placement Du Qu...,
  10% owner
• Management Partners Iv Lpen...,
  
• Partners Iv Lp Domain,
  10% owner
• Viii Founders Fund L P Kpcb,
  10% owner
• Russell Powers,
  Exec. VP Sales Int'l Ops
• Eileen M More,
  Director
• Keith Valentine,
  President
• Alexis V Lukianov,
  CEO and Chairman
• Michael E Paolucci,
  Exec. V.P., Global HR
• Craig E Hunsaker,
  SVP, Global Human Resources
• Richard Iii Treharne,
  Director
• Michael Lambert,
  CFO and Executive VP
• Robert J Hunt,
  Director
• Siddhartha Kadia,
  Director
• Amy Belt Raimundo,
  Director
• Michael Farrington,
  SVP, People and Culture
• Marc W. Rosenbaum,
  Chief Accounting Officer